Hospital-acquired infection are contaminations caused by bacteria, viral, and fungal pathogens. These infections are usually acquired in clinical and hospital settings mainly due to an infected patient, outside environment, or from the staff of that facility.

The global hospital-acquired infection diagnostics market was valued at $2,571 million in 2016 and is projected to reach $4,311 million by 2023, growing at a CAGR of 7.5% from 2017 to 2023. The urinary tract infections (UTI) segment accounted for the maximum share of the total market in 2016.

Download Sample Copy @ https://www.alliedmarketresearch.com/request-sample/4447

Rise in prevalence of infections from hospitals and clinical settings drive the market. However, the lack of awareness regarding hospital-acquired infection diagnostics impedes the market growth. Moreover, the technological advancements in healthcare sector for the innovation of novel and sophisticated products is projected to create lucrative opportunities for key market players.

Drug resistance testing segment is anticipated to maintain its dominance during the forecast period, accounting for major share of the global hospital-acquired infections diagnostics market. This is due to the benefits drug resistance testing offers such as they are cost-effective when the prevalence of drug resistance in chronically infected patients is low.

Major Key Players:

• Abbott Laboratories
• AdvanDX
• Alere Inc.
• AstraZeneca plc
• Bayer Schering Pharma LLC
• Becton Dickinson and Company
• Cepheid Inc.
• Roche AG

Key Findings of the Hospital-acquired Infection Diagnostics Market:

•The U.S. was the major shareholder in the North America hospital-acquired infection diagnostics market, and accounted for the highest share in 2016.

•Disease testing is expected to grow at the highest CAGR during 2017-2023.

•Japan occupied about two-ninths share of the total Asia-Pacific hospital-acquired infections diagnostics market in 2016.whereas, South Korea is expected to grow rapidly registering a CAGR of 8.3% during the forecast period.

•The immunoassay segment dominated the market in 2016, growing at a CAGR of 5.6% from 2017 to 2023.

•Molecular diagnostics accounted for about one fourth share of the total market share in 2016 and is expected to grow with a high CAGR of 12.8% during the forecast period.

Make an Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/4447